Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification

Sci Rep. 2022 Jan 10;12(1):362. doi: 10.1038/s41598-021-04237-0.

Abstract

Detrusor underactivity (DU) could be resulted from many different etiologies. Patients with DU might have reduced bladder sensation, low detrusor contractility, and large post-void residual volume. This study analyzed therapeutic outcome of active management for male DU patients, based on clinical and urodynamic characteristics. Male DU patients aged > 18 years old were retrospectively reviewed from the videourodynamic study (VUDS) records in recent 10 years. The patients' demographics, VUDS results, treatment modalities, and treatment outcome were analyzed. The treatment outcomes were compared among patients with different DU subgroups, clinical diagnosis and treatment modalities. Patients with voiding efficiency of > 66.7% were considered having a successful treatment outcome. For comparison, 30 men with normal VUDS finding served as the control arm. Most of the DU patients had reduced bladder sensation. The reduced bladder sensation is closely associated with low detrusor contractility. After active treatment, a successful outcome was achieved in 68.4% of patients after bladder outlet surgery, 59.1% after urethral botulinum toxin A injection, and 57.6% after medical treatment, but only 18.2% after conservative treatment. A successful treatment outcome was achieved in patients with an intact detrusor contractility, either low (69.2%) or normal voiding pressure (81.8%), and in patients with a normal or increased bladder sensation (78.1%). However, patients with detrusor acontractile (41.3%) or absent bladder sensation (17.9%) had less favorable treatment outcome after any kind of urological management. This study revealed that active management can effectively improve voiding efficiency in patients with DU. The normal bladder sensation, presence of adequate detrusor contractility, and bladder outlet narrowing during VUDS provide effective treatment strategy for DU patients. Among all management, BOO surgery provides the best treatment outcome.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine Release Inhibitors / therapeutic use
  • Aged
  • Aged, 80 and over
  • Botulinum Toxins, Type A / therapeutic use
  • Conservative Treatment* / adverse effects
  • Diagnostic Techniques, Urological*
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Recovery of Function
  • Retrospective Studies
  • Time Factors
  • Urethra / innervation*
  • Urinary Bladder / innervation*
  • Urinary Bladder, Underactive / diagnostic imaging
  • Urinary Bladder, Underactive / physiopathology
  • Urinary Bladder, Underactive / therapy*
  • Urodynamics*
  • Urologic Surgical Procedures, Male* / adverse effects
  • Urological Agents / adverse effects
  • Urological Agents / therapeutic use*
  • Video Recording*

Substances

  • Acetylcholine Release Inhibitors
  • Urological Agents
  • Botulinum Toxins, Type A
  • incobotulinumtoxinA